WM Setup Attractive but Valuation Still Rich: DeepValue Flags Execution Risks

What happened

Waste Management (WM) reaffirmed 2024 guidance and appears poised for positive earnings revisions as operational trends normalize post-Stericycle acquisition, with revenue of $26.4-$26.6B and free cash flow jumping 29% to $3.75-$3.85B. However, the DeepValue Master Report warns that the stock trades at ~34.5x P/E and 17.3x EV/EBITDA, roughly 200% above a conservative DCF estimate, offering a thin margin of safety. Elevated leverage at 3.64x net debt/EBITDA and heavy sustainability capex add balance-sheet risk, while integration of Stericycle, recycling, and RNG projects poses execution challenges. The news article highlights a 4.3% free cash flow yield and potential 21% upside to a $265 price target if 2027 targets are met, presenting a more attractive risk/reward. Yet the premium valuation leaves little room for error, and any missteps could trigger multiple compression.

Implication

With a 4.3% free cash flow yield and potential 21% upside to a $265 target if 2027 targets are met, the risk/reward has improved but remains balanced. The DeepValue report's SELL stance underscores the lack of a classic margin of safety at current multiples, with leverage and heavy capex limiting flexibility. Key catalysts include Stericycle margin improvement, deleveraging, and solid returns from sustainability investments, but any misstep could trigger multiple compression. The stock's 7.7% gain over the past 12 months suggests the market already prices in a smooth integration. For value-oriented investors, a trim or hold may be prudent until a more compelling entry emerges.

Thesis delta

The new article softens the DeepValue SELL stance by highlighting operational normalization and a 21% upside opportunity, but the fundamental risks around valuation and execution remain acute. The thesis shifts from 'potential sell' to a more neutral 'wait and see,' as the attractive free cash flow yield and guidance reaffirmation provide some near-term support. However, any deterioration in Stericycle profitability or FCF weakness could quickly reinstate a firmer sell bias.